An immunocompetent Merkel cell carcinoma model for preclinical studies
Authors:
- Monique E VerhaegenMVMonique E Verhaegen
- Kathrine L SingerKSKathrine L Singer
- Miranda BaumbickMBMiranda Baumbick
- Pei-Wei HuangPHPei-Wei Huang
- Li-Jyun SyuLSLi-Jyun Syu
- Dawn WilbertDWDawn Wilbert
- Avery SeligASAvery Selig
- Giselle A FarjoGFGiselle A Farjo
- Emily WalterEWEmily Walter
- Natalia WolinskiNWNatalia Wolinski
- Allison FurgalAFAllison Furgal
Preprint
Abstract
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that frequently carries integrated Merkel cell polyomavirus DNA and expresses oncogenic viral small T antigen (sTAg) and truncated large T antigen (tLTAg). We previously reported a mouse model of MCC with skin-targeted expression of sTAg, tLTAg, and the Merkel cell transcription factor ATOH1, combined with deletion of Trp53 . Here, we optimized this model to achieve 100% tumor penetrance with lymph node metastases, established four mouse MCC cell lines, and selected one line, mMCC2, for pilot preclinical trials. In immunocompetent C57BL/6J mice, mMCC2 cells reliably produce MCCs and lymph node metastases following subcutaneous or intradermal (orthotopic) injection, and liver and lung metastases after tail vein injection. Mouse MCC allografts resemble parental tumors histologically and express a full complement of MCC differentiation markers. Treatment of allografted mice with anti-PD-1 resulted in variable inhibition of tumor growth. In contrast, treatment with lysine-specific histone demethylase 1 (LSD1) inhibitors, with or without anti-PD-1, led to consistently lower tumor volumes by 5.7-fold in both groups (P< 0.0001) and smaller or undetectable lymph node metastases. Growth-inhibited tumors in all groups showed a marked reduction in proliferating tumor cells and increased infiltration by F4/80+ macrophages and CD8+ T cells. These findings support a role for immune-cell recruitment in treatment response and underscore the importance of immunocompetent preclinical models, even in studies using targeted therapies. This unique virus-positive MCC allograft model, which produces local tumors as well as regional and distant metastases in immunocompetent hosts, provides a critical platform for preclinical evaluation of new therapeutic strategies and sets the stage for much-needed translational studies to inform future clinical trials.Keywords
Funding Information
- National Cancer Institute (P30CA046592)
- National Cancer Institute (R01CA189352)
- National Cancer Institute (R01CA241947)
- National Cancer Institute (P01CA225517)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR075043)
- Linkou Chang Gung Memorial Hospital Research Scholar Program
- Autenrieth Merkel Cell Fund
- Taubman Institute Innovation Program, Taubman Institute, Michigan Medicine